Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Arzerra
Fourth PML Case With Tecfidera in MS Calls for Vigilance
The two faces of neuromyelitis optica.
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Current and future disease-modifying therapies in multiple sclerosis.
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Cognitive impairment in multiple sclerosis.

Pages